NAPRT and cancer: Cell-based assays clearly demonstrated that our best NAPRT inhibitor, compound 8 (4-hydroxynicotinic acid), but not 5-hydroxy or 6-hydroxynicotinic acid, exhibited marked anti-cancer activity when combined with FK866 while showing no significant growth inhibition when used alone.